- Case report
- Open Access
- Open Peer Review
Recurrent bacteremia with Helicobacter cinaedi: case report and review of the literature
- Ilker Uçkay†1,
- Jorge Garbino†1Email author,
- Pierre-Yves Dietrich2,
- Béatrice Ninet3,
- Peter Rohner3 and
- Véronique Jacomo3
© Uçkay et al; licensee BioMed Central Ltd. 2006
- Received: 22 November 2005
- Accepted: 23 May 2006
- Published: 23 May 2006
Helicobacter cinaedi is a rare pathogen in humans, occurring mostly in immuno-compromised patients, with a high potential for recurrence. We describe a case of a patient with lymphoma hospitalized for chemotherapy.
At admission, the patient presented with an indolent and non-prurigenic macular rash around her implantable venous access device. Gram staining of blood cultures revealed the presence of spiral-shaped gram-negative rods that could not be grown upon subculture. Helicobacter cinaedi was identified by PCR. No other symptoms or pathology were observed in a whole body CT scan. The implantable venous access device was removed and empiric therapy by ceftriaxone and gentamicin for 2 weeks was initiated, followed by peroral clarithromycin 2 × 500 mg/day and later by levofloxacin 2 × 500 mg/day for 7 weeks. Oncologic remission was achieved 3 months later. However, the patient was re-hospitalized 2 months later for fever, shivering, reappearance of the macular non-prurigenic rash, diarrhea, cough and asthenia. Blood cultures grew H. cinaedi. Multiple investigations could not identify the source. Empiric antibiotic therapy of ceftriaxone and doxycycline was started for 2 weeks with resolution of symptoms, followed by an oral combination of amoxicillin, metronidazole and doxycycline for 2 months; doxycycline was continued for another month. Bacteremia has not recurred for a period of 19 months.
Although H. cinaedi is considered to be a low virulent bacteria, its potential to cause recurrent bacteremia should not be underestimated. H. cinaedi could have an endovascular source of infection and should be treated for an adequate duration with combined antibiotherapy.
- Minimal Inhibitory Concentration
- Cytolethal Distend Toxin
- Congenital Origin
Morphological and genotype studies have shown that different Helicobacter species are involved in animal infections. Few cause diseases in humans .
Helicobacter species have been isolated from the stomach of various mammals, including dogs, cats, ferrets, pigs, monkeys and cheetahs, all of which are associated with various degrees of gastritis in their hosts. Helicobacter species have also been isolated from the intestinal tracts of humans, animals, and birds [2, 3]. The isolation of Helicobacter cinaedi from the colon, liver, and mesenteric lymph nodes of monkeys confirmed its association with hepatitis and colitis in monkeys .
Recent studies suggest that Helicobacter spp. are involved in cholesterol gallstones in mice and perhaps in humans .
Helicobacter cinaedi, formerly named Campylobacter cinaedi, is an unusual species in some reported series in the literature . This pathogen is found predominantly in severely immuno-compromised patients, such as cancer or AIDS patients. It often causes a non-lethal disease with a high potential for recurrence, requiring long antibiotic therapy for several months. H. cinaedi is difficult to grow on traditional culture media. In the majority of cases, diagnosis is possible by PCR. The source of infection is assumed to be intestinal, the hosts are a wide range of animals, especially hamsters. Asymptomatic carriage and infection in immuno-competent patients also occur.
In this report we describe a case of recurrent bacteremia with skin involvement in a patient undergoing chemotherapy; this is a rare clinical presentation. The clinical aspects, therapy pitfalls, a review of the literature and microbiological difficulties are discussed.
A 53-year-old Caucasian woman without past medical history was hospitalized in August 2003 in our institution because of crippling ischialgic pain in her left leg. Investigations revealed a lesion in the left paravertebral and epidural region of the lumbar spine infiltrating the ipsilateral psoas without metastasis.
Because of exacerbated pain, the appearance of pariesis (difficulty with dorsal flexion of the foot) in her left leg and a large number of differential diagnosis, resection of the paravertebral mass was performed and a portacath was inserted. Histological examination showed a large B-cell lymphoma stage IE. Four cycles of chemotherapy were scheduled with cyclophosphamide, doxorubicin, vincristine and prednisolone in association with methotrexate and monoclonal anti-CD20 antibody. The patient tolerated the first cycle well; agranulocytosis appeared for 4 days (neutrophil count 180 g/l). The leg paresis subsided completely.
At admission for the second cycle of chemotherapy in September 2003, a transient pink macular rash appeared around the skin orifice of the implantable venous access device. No other clinical symptoms were present. Laboratory examinations revealed a C-reactive protein (CRP) of 29 mg/l and a left shift in the leukocyte count of 8%. This slight inflammation could not be explained by the lymphoma alone since previous CRP values were within the normal range. Blood cultures were performed. The rash disappeared spontaneously and the patient became asymptomatic.
Blood cultures were performed using an automated blood culture system (Bactec 9240 Becton Dickinson Diagnostic Instrument Systems, Sparks, MD, USA).
Additional blood cultures indicated the presence of the same micro-organism and empiric antibiotic therapy with intravenous ceftriaxone 1 × 2 g/day and a catheter lock technique with gentamicin 5 mg/day was administered for 2 weeks.
Despite significant regression of all inflammatory parameters, control blood cultures remained positive for the same organism. The implantable venous access device was removed since an infection of the central vascular access was suspected in absence of another clinical symptoms. Cultures of the implantable venous access device remained negative but bacteremia persisted for another 4 days suggesting another source. However, no other source was found. A whole body computer tomography (CT) scan did not reveal any suspect lesions. Magnetic resonance imaging (MRI), performed due to a headache, revealed an aneurysm, 8 mm in diameter, in the left posterior communicating artery (P2-P3). Coiling was performed with the placement of a detachable platinum coil, believed to be less susceptible to infections than other metals. Discussion arose whether this aneurysm could be of mycotic or congenital origin. No biopsy for histological analysis could be obtained and no previous cerebral images existed. The presence of an aneurysm in a region known for congenital aneurisms led us to diagnose a congenital origin.
After the intravenous treatment, an oral regimen of clarithromycin 2 × 500 mg/day followed by levofloxacin 2 × 500 mg/day was administered for 7 weeks.
The patient underwent three cycles of chemotherapy and 40 Gy of radiotherapy. In January 2004, the patient was considered to be in complete remission with good clinical evolution and she returned to work; the only complaint was symmetric arthralgia in the elbows and knees of unknown origin.
However, in March 2004, the patient was re-hospitalized due to a fever (39°C), shivering, watery diarrhea, vomiting, fatigue, unproductive cough, and a diffuse, red, macular, patchy cutaneous rash all over the body with the exception of mucosal surfaces. The initial suspicion of a viral infection was revised 5 days later when a spiral gram-negative rod was detected in the blood cultures. The CD4 count revealed 290 cells/mm3 attributed to her chemotherapeutic immuno-compromised state. During this second episode of bacteremia, positive blood cultures again revealed a spiral, helical gram-negative rod (figure 1B). This time, subcultures were successful; colonies grew on blood agar incubated in a micro-aerobic (5% O2) atmosphere. Again, the identification of H. cinaedi was obtained by PCR and sequencing of the 16S rRNA gene.
Minimal inhibitory concentrations (MIC) of potentially active antimicrobials were determined on blood agar incubated micro-aerobically at 35°C with the E-test method for clarithromycin, ciprofloxacin, erythromycin, trimethoprim-sulfamethoxazole, metronidazole and amoxicillin. Interpretation of susceptibility in vitro was based on the NCCLS guidelines for H. pylori for clarithromycin, and on published reports for metronidazole and amoxicillin [7, 8]. For the other antibiotics, the interpretation was based on the NCCLS guidelines for gram-negative bacilli. The strain was susceptible to amoxicillin (MIC = 0.75 mg/l) and to metronidazole (MIC = 0.25 mg/l), intermediate to clarithromycin (MIC = 3 mg/l) and resistant to the other antibiotics tested (erythromycin, trimethoprim-sulfamethoxazole and ciprofloxacin).
After 2 weeks of successful intravenous ceftriaxone 1 × 2 g/day and peroral doxycycline 2 × 100 mg/day therapy, this regimen was changed to a peroral outpatient treatment. The patient received doxycycline 2 × 100 mg/day, metronidazole 3 × 500 mg/day and amoxicillin 3 × 750 mg/day for 2 months followed by doxycycline alone for a third month, following an empiric eradication therapy for Helicobacter pylori. The patient had a good laboratory and clinical response.
Multiple examinations were repeated in order to detect the possible source of the recurrent infections, such as whole body CT scan, transesophageal echocardiography, bacterial stool cultures, colonoscopy with multiple biopsies, bone scintigraphy and cerebral angiographic MRI. No pathology, no recurrent neoplastic disease or cerebral aneurysms were found. An unspecific inflammation was seen in the colonoscopy without histological evidence of bacterial infection. This observation was attributed to the patient's post-irradiation status. Further investigations were abandoned due to the favorable progress under antibiotic therapy. The source of the recurrent infection could not be identified but was presumed to be either of endovascular or intestinal origin.
In November 2005, 19 months after the recurrence, the patient is in complete remission and in good clinical condition.
Like other non-pylori Helicobacters, H. cinaedi is an unusual pathogen in humans and difficult to culture with the normal routine procedures. Since the first cases of proctocolitis in male AIDS patients were described in 1985 , several other cases have been reported in the literature. Asymptomatic carriage certainly occurs. The micro-organism, considered to be enterohepatic, seems to have a low degree of virulence. It is regarded as an opportunist. Recently, Taylor et al.  reported for the first time an important putative virulence factor in H. cinaedi confirmed by the production of cytolethal distending toxin, which causes distention in cells and arrest in the G2/M phase of cell division. Also motility by means of flagella is generally regarded as a virulence determinant in Helicobacter and Campylobacter species. H. cinaedi shares the production of cytolethal distending toxin with other enteric pathogenic species. H. cinaedi may cause symptomatic diseases in immuno-compromised patients, such as those with HIV, cancer or after transplantation [9, 11–18].
Rare cases of disease in immuno-competent patients have been reported [19, 20]: a patient with bacteremia and arthritis  or erysipelas , several patients with recurrent fever and rash , and in neonates . Interestingly, all immuno-competent patients and neonates with H. cinaedi disease had been in contact with animals . Other cases of bacteremia in immuno-compromised patients after renal failure  and X-linked agammaglobulinemia  have also been published in the literature.
The route of infection is rarely known, and presumed to be oral. As a reservoir, H. cinaedi has been identified in many animals, for example, rats, hamsters, dogs, cats, foxes, poultry, wild birds, and monkeys. Hamsters, in particular, are known to be a common natural reservoir . The role of the micro-organism in these animal hosts is unknown. Interestingly, our patient's daughter, living in the same household, fed her pet snake with rats. The snake died several months before the mother's illness. Perhaps both mother and daughter have been asymptomatically infected for a long time by the rats the snake was fed with. Rats are known to be carriers of H. cinaedi . Symptoms could have emerged in the mother after immuno-suppressive chemotherapy. We assume that the patient would not have experienced the H. cinaedi infection without the associated lymphoma and the chemotherapy. Cultures from the daughter were not possible to perform.
H. cinaedi infections may present various clinical manifestations, ranging from proctocolitis , gastroenteritis , meningitis in neonates , localized pain , rash, or bacteremia . The more immuno-compromised the patients, the more severe are the symptoms. Nevertheless, Kiehlbauch et al.  reported that two symptoms are predominant, namely fever and rash . Our case presented both symptoms, whereas the additional symptoms of diarrhea and arthralgia are less frequently reported . In our case, H. cinaedi could not be isolated from the colonoscopic biopsies and stool cultures. Other infectious agents could not be identified in the stool cultures.
The origin of the first bacteremia in our case remains unknown but we have assumed it to be the gastrointestinal tract since the mucosal cells have been damaged by combined chemo- and radiotherapy.
Our investigations revealed a cerebral aneurysm of the posterior communicating artery. Its localization and its single status indicate a possible congenital origin. No new aneurysms or change in size were observed during the second episode of bacteremia. A whole body angiography of the large arteries did not reveal an endovascular origin.
H. cinaedi is a fastidious organism, rendering microbiological diagnosis difficult. It rarely grows on traditional culture media . At best, growth may be obtained on rich, non-selective media (blood or chocolate agar) incubated in a micro-aerobic (5% O2) atmosphere at 35°C . The diagnosis is mainly established by gene amplification techniques such as PCR and subsequent sequencing . With these techniques, however, antimicrobial susceptibility in vitro cannot be determined.
No clear guidelines are available in the literature concerning the choice or duration of antibiotic therapy. Many antibiotic agents, alone or in combination, have been successfully used, such as penicillin, ampicillin, cefazolin, erythromycin, ciprofloxacin, aminoglycosides, tetracyclines and rifampicin [11, 19, 21, 29]. A large review of 23 cases of bacteremia reported that penicillins, tetracycline, and aminogylcosides are more effective than cephalosporins, erythromycin, or ciprofloxacin. Erythromycin resistant H. cinaedi has also been identified . Quinolones alone may not completely eradicate H. cinaedi, which explains the frequent reports of recurrent disease after quinolone monotherapy .
The reported duration of antibiotherapy for H. cinaedi bacteremia ranges from 10 days to 12 weeks [19, 29]. Due to the frequent recurrences, prolonged antibiotic treatment is necessary [11–13]. In our case, a 2-week course of combined antibiotherapy with ceftriaxone and gentamicin, followed by 5 weeks of peroral clarithromycin and levofloxacin was not able to eradicate the micro-organism despite its susceptibility in vitro. Other possible reasons that could explain the recurrent illness were excluded, such as malabsorption, suspected malcompliance or macroscopic intestinal lesions. We therefore chose to treat the second recurrent episode for a sufficiently long 3-month period; so far it has been successful.
In conclusion, we report that recurrent bacteremia due to H. cinaedi without any anatomic lesion may occur; the micro-organism may re-emerge and prolonged antibiotic treatment is necessary. Optimal antimicrobial treatment and its duration remain to be established.
- De Groote D, Ducatelle R, Haesebrouck F: Helicobacters of possible zoonotic origin: a review. Acta Gastroenterol Belg. 2000, 63: 380-7.PubMedGoogle Scholar
- Zenner L: Pathology, diagnosis and epidemiology of the rodent Helicobacter infection. Comp Immunol Microbiol Infect Dis. 1999, 22: 41-61. 10.1016/S0147-9571(98)00018-6.View ArticlePubMedGoogle Scholar
- Fox JG: The expanding genus of Helicobacter: pathogenic and zoonotic potential. Semin Gastrointest Dis. 1997, 8: 124-41.PubMedGoogle Scholar
- Fox JG, Handt L, Sheppard BJ, Xu S, Dewhirst FE, Motzel S, Klein H: Isolation of Helicobacter cinaedi from the colon, liver, and mesenteric lymph node of a rhesus monkey with chronic colitis and hepatitis. J Clin Microbiol. 2001, 39: 1580-5. 10.1128/JCM.39.4.1580-1585.2001.View ArticlePubMedPubMed CentralGoogle Scholar
- Maurer KJ, Ihrig MM, Rogers AB, Ng V, Bouchard G, Leonard MR, Carey MC, Fox JG: Identification of cholelithogenic enterohepatic helicobacter species and their role in murine cholesterol gallstone formation. Gastroenterology. 2005, 128: 1023-33. 10.1053/j.gastro.2005.01.008.View ArticlePubMedGoogle Scholar
- Skirrow MB, Jones DM, Sutcliffe E, Benjamin J: Campylobacter bacteraemia in England and Wales, 1981–91. Epidemiol Infect. 1993, 110: 567-73.View ArticlePubMedPubMed CentralGoogle Scholar
- Kim JJ, Reddy R, Lee M, Kim JG, El-Zaatari FA, Osato MS, Graham DY, Kwon DH: Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother. 2001, 47: 459-61. 10.1093/jac/47.4.459.View ArticlePubMedGoogle Scholar
- Lopez-Brea M, Martinez MJ, Domingo D, Alarcon T: A 9 year study of clarithromycin and metronidazole resistance in Helicobacter pylori from Spanish children. J Antimicrob Chemother. 2001, 48: 295-7. 10.1093/jac/48.2.295.View ArticlePubMedGoogle Scholar
- Totten PA, Fennell CL, Tenover FC, Wezenberg JM, Perine PL, Stamm WE, Holmes KK: Campylobacter cinaedi (sp.nov.). and Campylobacter fennelliae (sp.nov.): two new Campylobacter species associated with enteric disease in homosexual men. J Infect Dis. 1985, 151: 131-9.View ArticlePubMedGoogle Scholar
- Taylor NS, Ge Z, Shen Z, Dewhirst FE, Fox JG: Cytolethal distending toxin: a potential virulence factor for Helicobacter cinaedi. J Infect Dis. 2003, 188: 1892-7. 10.1086/379837.View ArticlePubMedGoogle Scholar
- Kiehlbauch JA, Tauxe RV, Baker CN, Wachsmuth IK: Helicobacter cinaedi-associated bacteremia and cellulitis in immunocompromised patients. Ann Int Med. 1994, 121: 90-3.View ArticlePubMedGoogle Scholar
- Tee W, Street AC, Spelman D, Munckhof W, Mijch A: Helicobacter cinaedi bacteraemia: varied clinical manifestations in three homosexual males. Scand J Infect Dis. 1996, 28: 199-203.View ArticlePubMedGoogle Scholar
- Sullivan AK, Nelson MR, Walsh J, Gazzara BG: Recurrent Helicobacter cinaedi cellulites and bacteremia in patient with HIV infection. Int J STD AIDS. 1997, 8: 59-60. 10.1258/0956462971918634.View ArticlePubMedGoogle Scholar
- Cimolai N, Gill MJ, Jones A, Flores B, Stamm WE, Laurie W, Madden B, Shahrabadi MS: "Campylobacter cinaedi" bacteremia: case report and laboratory findings. J Clin Microbiol. 1987, May: 942-3.Google Scholar
- Hung CC, Hsueh PR, Chen MY, Teng LJ, Chen YC, Luh KT, Chuang CY: Bacteremia caused by Helicobacter cinaedi in an AIDS patients. J Formos Med Assoc. 1997, 96: 558-60.PubMedGoogle Scholar
- Mammen MP, Aronson NE, Edenfield WJ, Endy TP: Recurrent Helicobacter cinaedi bacteremia in a patient infected with human immunodeficiency virus: case report. Clin Infect Dis. 1995, 21: 1055-View ArticlePubMedGoogle Scholar
- Burman WJ, Cohn DL, Reves RR, Wilson ML: Multifocal cellulites and monoarticular arthritis as manifestations of Helicobacter cinaedi bacteremia. Clin Infect Dis. 1995, 20: 564-70.View ArticlePubMedGoogle Scholar
- Kemper CA, Mickelsen P, Morton A, Walton B, Deresinski SC: Helicobacter, (Campylobacter) fennelliae-like organisms as an important but occult cause of bacteraemia in a patient with AIDS. J Infect. 1993, 26: 97-101. 10.1016/0163-4453(93)97128-K.View ArticlePubMedGoogle Scholar
- Lasry S, Simon J, Marais A, Pouchot J, Vinceneux P, Boussougant Y: Helicobacter cinaedi septic arthritis and bacteremia in an immunocompetent patient. Clin Infect Dis. 2000, 31: 201-2. 10.1086/313930.View ArticlePubMedGoogle Scholar
- Van Genderen PJ, Goessens WH, Petit PL: Helicobacter cinaedi-associated bacteraemia and erysipelas in an immunocompetent host: a diagnostic challenge. Scand J Infect Dis. 2005, 37: 382-5.View ArticlePubMedGoogle Scholar
- Orlicek SL, Welch DF, Kuhls TL: Septicemia and meningitis caused by Helicobacter cinaedi in a neonate. J Clin Microbiol. 1993, 31: 569-71.PubMedPubMed CentralGoogle Scholar
- Murakami H, Goto M, Ono E, Sawabe E, Iwata M, Okuzumi K, Yamaguchi K, Takahashi T: Isolation of Helicobacter cinaedi from blood of an immunocompromise patient in Japan. J Infect Chemother. 2003, 9: 344-7. 10.1007/s10156-003-0265-3.View ArticlePubMedGoogle Scholar
- Simons E, Spacek LA, Lederman HM, Winkelstein JA: Helicobacter cinaedi bacteremia presenting as macules in an afebrile patient with X-linked agammaglobulinemia. Infection. 2004, 32: 367-8. 10.1007/s15010-004-3152-7.View ArticlePubMedGoogle Scholar
- Fernandez KR, Hansen LM, Vandamme P, Beaman BL, Solnick JV: Captive Rhesus monkeys (Macaca mulatta) are commonly infected with Helicobacter cinaedi. J Clin Microbiol. 2002, 40: 1908-12. 10.1128/JCM.40.6.1908-1912.2002.View ArticlePubMedPubMed CentralGoogle Scholar
- Vandamme P, Harrington CS, Jalava K, On SLW: Misidentifying Helicobacters: the Helicobacter cinaedi example. J Clin Microbiol. 2000, 38: 2261-6.PubMedPubMed CentralGoogle Scholar
- Grayson ML, Tee W, Dwyer B: Gastroenteritis associated with Campylobacter cinaedi. Med J Aust. 1989, 150: 214-5.PubMedGoogle Scholar
- Van der Ven AJ, Kullberg BJ, Vandamme P, Meis JF: Helicobacter cinaedi bacteremia associated with localized pain but not with cellulitis. Clin Infect Dis. 1996, 22: 710-11.View ArticlePubMedGoogle Scholar
- Pena JA, McNeil K, Fox JG, Versalovic J: Molecular evidence of Helicobacter cinaedi organisms in human gastric biopsy specimens. J Clin Microbiol. 2002, 40: 1511-13. 10.1128/JCM.40.4.1511-1513.2002.View ArticlePubMedPubMed CentralGoogle Scholar
- Sacks LV, Labriola AM, Gill VJ, Gordin FM: Use of ciprofloxacin for successful eradication of bacteremia due to Campylobacter cinaedi in a human immunodeficiency virus-infected person. Rev Infect Dis. 1991, 13: 1066-8.View ArticlePubMedGoogle Scholar
- Kuijper EJ, Stevens S, Imamura T, De Wever B, Claas EC: Genotypic identification of erythromycin-resistant Campylobacter isolates as Helicobater species and analysis of resistance mechanism. J Clin Microbiol. 2003, 41: 3732-6. 10.1128/JCM.41.8.3732-3736.2003.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/6/86/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.